Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in ...
Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
Atopic dermatitis, a chronic skin condition, is common in children and requires treatment to minimise frequent flares. Dr Ker ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic dermatitis not adequately controlled with topical ...
FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic ...